Scope of this summary
Children and adults with suspected or established asthma in ambulatory care. The US NAEPP 2020 report is a focused update to the 2007 national guideline rather than a complete replacement; this summary therefore keeps its six updated topics distinct from the broader 2026 GINA strategy. Pregnancy, occupational asthma, difficult-to-treat disease and acute critical care require their dedicated pathways.
The Bottom Line
- Establish a compatible pattern of variable respiratory symptoms and document variable expiratory airflow whenever feasible; reconsider mimics when symptoms, examination and objective results do not align.
- Provide inhaled-corticosteroid-containing treatment rather than relying on a short-acting bronchodilator alone; select the age-appropriate NAEPP or GINA strategy deliberately and document which framework is being followed.
- NAEPP conditionally recommends single maintenance and reliever therapy with inhaled corticosteroid-formoterol for appropriate patients aged four years or older with moderate to severe persistent asthma, within the report鈥檚 stated evidence and age boundaries.
- At every review, assess current symptoms, exacerbations, oral-steroid exposure, lung function, inhaler technique, adherence, access, triggers and comorbidities before escalating medication.
- Give a written, understandable action plan that explains routine treatment, how to recognize deterioration, reliever instructions and when to obtain urgent help.
Practical clinical workflow
1
Take a symptom and trigger history, including night waking, exercise, viral illness, smoke, allergens, work exposures and prior emergency care; examine for alternative cardiopulmonary or upper-airway causes.
2
Perform spirometry with bronchodilator response when age and circumstances permit; use repeat testing, peak-flow variability or other source-supported tests when initial spirometry is nondiagnostic.
3
Classify control and future risk, choose an age-appropriate anti-inflammatory regimen, demonstrate the device, check affordability and record the intended reliever strategy.
4
Arrange early reassessment after a treatment change or exacerbation; step up only after correctable causes are addressed and consider a cautious step down after sustained control with follow-up.
5
Refer when the diagnosis remains uncertain, occupational disease is possible, control requires high-intensity treatment, serious adverse effects occur or exacerbations continue despite optimized basics.
Safety boundaries and escalation
- Severe breathlessness, inability to speak normally, cyanosis, exhaustion, confusion, a silent chest, poor response to reliever treatment or rapidly declining airflow requires emergency assessment.
- Repeated short-acting bronchodilator use, repeated systemic corticosteroid courses or recent emergency care signals high future risk even when today鈥檚 symptoms appear limited.
- Confirm product-specific FDA age indications, device instructions, dose ceilings and insurance formulary before prescribing; NAEPP and GINA inhaler terminology is not itself a US product label.
- Do not let a normal examination between episodes exclude asthma, and do not continue indefinite escalation without rechecking diagnosis, technique, adherence, exposures and comorbidity.
Localization
US clinicians commonly work from the NAEPP focused updates while also consulting current GINA strategy; these sources are not identical. State scope-of-practice rules, FDA labeling, formulary coverage, school medication forms and access to spirometry affect implementation.
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- National Asthma Education and Prevention Program Coordinating Committee, National Heart, Lung, and Blood Institute2020 Focused Updates to the Asthma Management GuidelinesDOI 10.1016/j.jaci.2020.10.003 路 published 2020-12-03 路 updated 2021-02-01 路 accessed 2026-08-20view source
- Global Initiative for AsthmaGlobal Strategy for Asthma Management and Prevention2026 update 路 accessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.